Search Results

There are 21139 results for: content related to: Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in C rohn's disease

  1. You have free access to this content
    ACR Meeting

    Arthritis & Rheumatism

    Volume 64, Issue S10, October 2012, Pages: S1–S1216,

    Version of Record online : 11 OCT 2012, DOI: 10.1002/art.37735

  2. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  3. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 18, Issue 12, December 2012, Pages: 2209–2217, Casper Steenholdt, Magid Al-khalaf, Jørn Brynskov, Klaus Bendtzen, Ole Ø. Thomsen and Mark A. Ainsworth

    Version of Record online : 16 FEB 2012, DOI: 10.1002/ibd.22910

  4. You have free access to this content
    Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels

    Clinical & Experimental Immunology

    Volume 172, Issue 1, April 2013, Pages: 54–62, L. Semerano, J. Biton, L. Delavallée, E. Duvallet, E. Assier, N. Bessis, E. Bernier, O. Dhellin, G. Grouard-Vogel and M.-C. Boissier

    Version of Record online : 10 MAR 2013, DOI: 10.1111/cei.12040

  5. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

    Inflammatory Bowel Diseases

    Volume 18, Issue 9, September 2012, Pages: 1628–1633, Uri Kopylov, Yoav Mazor, Miri Yavzori, Ella Fudim, Lior Katz, Daniel Coscas, Orit Picard, Yehuda Chowers, Rami Eliakim and Shomron Ben-Horin

    Version of Record online : 29 OCT 2011, DOI: 10.1002/ibd.21919

  6. You have free access to this content
    Print Only

    Journal of Gastroenterology and Hepatology

    Volume 28, Issue S3, October 2013, Pages: 694–919,

    Version of Record online : 17 SEP 2013, DOI: 10.1111/jgh.12363_3

  7. You have free access to this content
    Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

    Alimentary Pharmacology & Therapeutics

    Volume 37, Issue 12, June 2013, Pages: 1172–1183, C. Steenholdt, Y. Palarasah, K. Bendtzen, A. Teisner, J. Brynskov, B. Teisner and C. H. Nielsen

    Version of Record online : 7 MAY 2013, DOI: 10.1111/apt.12330

  8. You have free access to this content
    Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

    Inflammatory Bowel Diseases

    Volume 18, Issue 5, May 2012, Pages: 985–1002, Charlotte I. de Bie, Johanna C. Escher and Lissy de Ridder

    Version of Record online : 20 SEP 2011, DOI: 10.1002/ibd.21871

  9. Changes in the pattern of cytokine production from peripheral blood mononuclear cells in patients with rheumatoid arthritis treated with infliximab and their relation to plasma arginase activity

    International Journal of Rheumatic Diseases

    Fumihiko Miyoshi, Kojiro Sato and Toshihide Mimura

    Version of Record online : 12 MAY 2016, DOI: 10.1111/1756-185X.12864

  10. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis

    Journal of Gastroenterology and Hepatology

    Volume 29, Issue 6, June 2014, Pages: 1177–1185, Michael J Hayes, Adam C Stein and Atsushi Sakuraba

    Version of Record online : 15 MAY 2014, DOI: 10.1111/jgh.12517

  11. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF

    Inflammatory Bowel Diseases

    Volume 16, Issue 11, November 2010, Pages: 1898–1904, Akihiro Yamada, Koji Sono, Nobuo Hosoe, Nobuo Takada and Yasuo Suzuki

    Version of Record online : 22 MAR 2010, DOI: 10.1002/ibd.21259

  12. Drug Interaction Effects on Antitumour Drugs (VIII): Prevention of Ifosfamide-Induced Urotoxicity by Disulfiram and its Effect on Antitumour Activity and Acute Toxicity of Alkylating Agents in Mice

    Pharmacology & Toxicology

    Volume 68, Issue 1, January 1991, Pages: 21–25, Masaaki Ishikawa, Yoshio Takayanagi and Ken-ichi Sasaki

    Version of Record online : 25 MAR 2009, DOI: 10.1111/j.1600-0773.1991.tb01202.x

  13. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone

    British Journal of Dermatology

    Volume 172, Issue 3, March 2015, Pages: 760–768, R.P. Hall III, J. Fairley, D. Woodley, V.P. Werth, D. Hannah, R.D. Streilein, J. McKillip, J. Okawa, M. Rose, L.L. Keyes-Elstein, A. Pinckney, A. Overington, J. Wedgwood, L. Ding and B. Welch

    Version of Record online : 5 FEB 2015, DOI: 10.1111/bjd.13350

  14. Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)

    Inflammatory Bowel Diseases

    Volume 18, Issue 11, November 2012, Pages: 2043–2055, Daniel A. Sussman, Nisa Kubiliun, Parvez M. Mulani, Jingdong Chao, Carol A.T. Gillis, Mei Yang, Mei Lu and Maria T. Abreu

    Version of Record online : 12 JAN 2012, DOI: 10.1002/ibd.22873

  15. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus

    Journal of Gastroenterology and Hepatology

    Volume 25, Issue 5, May 2010, Pages: 886–891, Shuji Yamamoto, Hiroshi Nakase, Minoru Matsuura, Yusuke Honzawa, Satohiro Masuda, Ken-ichi Inui and Tsutomu Chiba

    Version of Record online : 7 DEC 2009, DOI: 10.1111/j.1440-1746.2009.06206.x

  16. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice

    Alimentary Pharmacology & Therapeutics

    Volume 42, Issue 5, September 2015, Pages: 529–539, D. J. Buurman, J. M. Maurer, R. J. Keizer, J. G. W. Kosterink and G. Dijkstra

    Version of Record online : 26 JUN 2015, DOI: 10.1111/apt.13299

  17. You have free access to this content
    Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

    Alimentary Pharmacology & Therapeutics

    Volume 34, Issue 1, July 2011, Pages: 51–58, C. Steenholdt, M. Svenson, K. Bendtzen, O. Ø. Thomsen, J. Brynskov and M. A. Ainsworth

    Version of Record online : 3 MAY 2011, DOI: 10.1111/j.1365-2036.2011.04682.x

  18. Gastroenterologists' prescribing of infliximab for Crohn's disease: A national survey

    Inflammatory Bowel Diseases

    Volume 15, Issue 10, October 2009, Pages: 1467–1475, Meaghan St. Charles, Sheila R. Weiss Smith, Robert Beardsley, Donald O. Fedder, Olivia Carter-Pokras and Raymond K. Cross

    Version of Record online : 5 MAR 2009, DOI: 10.1002/ibd.20904

  19. You have free access to this content
    Poster Presentations

    Journal of Gastroenterology and Hepatology

    Volume 28, Issue S3, October 2013, Pages: 23–693,

    Version of Record online : 17 SEP 2013, DOI: 10.1111/jgh.12363_2

  20. Efficacy and safety of infliximab in treating patients with ulcerative colitis: Experiences from a single medical center in southern China

    Journal of Digestive Diseases

    Volume 15, Issue 9, September 2014, Pages: 483–490, You Lian Zhou, Shan Xie, Pu Wang, Ting Zhang, Min Yi Lin, Jia Sheng Tan, Fa Chao Zhi, Bo Jiang and Ye Chen

    Version of Record online : 1 SEP 2014, DOI: 10.1111/1751-2980.12161